COVID-19 (SARS-CoV-2 infection) in persons who were previously given the BCG vaccine Infections and Infestations
Conditions
Interventions
This study looks at patient records from participants in an earlier study who were randomised to receive either vaccination with BCG vaccine produced in Brazil using the Moreaux (Rio de Janeiro) strai
Sponsors
National Council for Scientific and Technological Development
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants from the BCGREVAC trial (1996 - 1998) who were diagnosed or died from COVID-19 from January 27, 2020, onwards.
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Mortality from COVID-19 measured using patient records at a single timepoint | — |
Primary
| Measure | Time frame |
|---|---|
| Measured using patient records at a single timepoint: 1. COVID-19 incidence 2. COVID-19 severity (COVID-19 severity classification: 1) SpO2 < 95% on room air at sea level; 2) vigorous breathing effort; 3) cyanosis; 4) severe pneumonia; 5) Severe Acute Respiratory Syndrome (SARS); 6) sepsis; 7) septic shock) | — |
Countries
Brazil
Outcome results
None listed